CUV — Clinuvel Pharmaceuticals Income Statement

0.000.00%

Last trade - 00:00

HealthcareBalancedSmall CapNeutral

Annual income statement for Clinuvel Pharmaceuticals, fiscal year end - June 30th, AUD millions except per share, conversion factor applied.

	2021 June 30th	2022 June 30th	2023 June 30th	2024 June 30th	2025 June 30th
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS	ARS
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	48.3	66.2	82.2	95.5	95
Cost of Revenue
Gross Profit	50.2	64.8	89.9	96.6	93.2
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Total Operating Expenses	19.6	30.2	34.2	39.6	49.3
Operating Profit	28.7	36	48	55.9	45.7
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	25.7	34.3	45.6	50.7	51.6
Provision for Income Taxes
Net Income After Taxes	24.7	20.9	30.6	35.6	36.2
Net Income Before Extraordinary Items
Net Income	24.7	20.9	30.6	35.6	36.2
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	24.7	20.9	30.6	35.6	36.2
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	0.479	0.4	0.59	0.691	0.718
Dividends per Share